Progress: Procedure completed
| Role | Committee | Rapporteur | Shadows |
|---|---|---|---|
| Lead | PETI |
MONTSERRAT Dolors ( EPP)
|
GANCIA Gianna ( ID),
ZŁOTOWSKI Kosma ( ECR)
|
Lead committee dossier:
Legal Basis:
RoP 136-p5
Legal Basis:
RoP 136-p5Events
The European Parliament adopted by 458 votes to 149, with 86 abstentions, a resolution on EU transparency in the development, purchase and distribution of COVID-19 vaccines.
Increased transparency
The resolution underlined that the handling of the COVID-19 pandemic is a trust test for all Member States and EU institutions that will inform the response to possible future public health emergencies. Full transparency regarding all details of research into and the development, purchase and distribution of COVID-19 vaccines is the fundamental prerequisite for enhancing citizens’ trust in vaccines and the way in which institutions have spent huge amounts of public funds.
The Commission and the Member States are obliged to work as openly as possible and as closely as possible to the citizens when negotiating the COVID-19 vaccine contracts with pharmaceutical companies. However, the Commission refuses to disclose the names of the experts or even the seven Member States represented in the joint negotiation team.
Accountability
Given that democratic accountability is a prerequisite if the EU’s vaccine strategy is to play an efficient and credible role in global vaccination efforts, Members stressed that the Commission must adequately and efficiently inform Parliament of all aspects of the budgetary implications of research, development, negotiations, distribution and roll-out of COVID-19 vaccines in the EU, so that Parliament can fully exercise its duty to scrutinise the implementation of the EU budget.
Parliament expressed its deepest regret on the lack of transparency from the Commission, the Member States and pharmaceutical companies in the development, purchase and distribution of COVID-19 vaccines, especially in context of continuous breaches of contracts signed. It emphasised the limitations it has been subjected in its role as co-legislator owing to the opacity of the vaccine strategy adopted by the Commission, which has prevented it from being able to exercise effective control over the vaccine purchase and distribution process, nullifying its ability to scrutinise the correct application of the Union budget.
The Commission is called on to:
- improve its communication with the public regarding the EU strategy for COVID-19 vaccines;
- present a legislative proposal on future joint vaccine procurement with clear provisions on transparency and competence distribution among the actors of the EU institutional framework and the Member States and on future treatments against COVID-19 and orphan treatments within the framework of the pharmaceutical strategy for Europe;
- review the terms of price confidentiality agreements to address the current fragmentation of the European internal market;
- disclose the members of the teams involved in negotiating advance purchase agreements and purchase agreements with pharmaceutical companies for the purchase of COVID-19 vaccines;
- ensure full transparency by publishing non-redacted versions of the advance purchase agreements and purchase agreements;
- reveal the prices per dose for each manufacturer’s vaccine ;
- provide Parliament with detailed information on how EU payments were used by the contracted companies;
- publish and assess the EU’s global strategy to ensure the fast and equitable distribution of vaccines worldwide, including its involvement in the COVAX initiative, C-TAP and the cross-border supply of materials needed for vaccine production.
Documents
- Commission response to text adopted in plenary: SP(2022)67
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament: T9-0435/2021
- Motion for a resolution: B9-0519/2021
- Motion for a resolution: B9-0520/2021
- Debate in Parliament: Debate in Parliament
- Oral question/interpellation by Parliament: B9-0033/2021
- Amendments tabled in committee: PE693.701
- Amendments tabled in committee: PE693.701
- Oral question/interpellation by Parliament: B9-0033/2021
- Motion for a resolution: B9-0519/2021
- Motion for a resolution: B9-0520/2021
- Commission response to text adopted in plenary: SP(2022)67
Activities
- Rainer WIELAND
- Joachim KUHS
Plenary Speeches (1)Institutional Motions (1)
- Dolors MONTSERRAT
Plenary Speeches (1)Institutional Motions (1)
- Angel DZHAMBAZKI
Plenary Speeches (1)
- Eleonora EVI
Plenary Speeches (1)
- Jytte GUTELAND
Plenary Speeches (1)
- Krzysztof HETMAN
Plenary Speeches (1)
- Seán KELLY
Plenary Speeches (1)
- Tilly METZ
Plenary Speeches (1)
- João PIMENTA LOPES
Plenary Speeches (1)
- Jiří POSPÍŠIL
Plenary Speeches (1)
- Valter FLEGO
Plenary Speeches (1)
- Sira REGO
Plenary Speeches (1)
- Gunnar BECK
Plenary Speeches (1)
- Marc BOTENGA
Plenary Speeches (1)
- Nicolaus FEST
Plenary Speeches (1)
- Jaak MADISON
Institutional Motions (1)
- Ivan Vilibor SINČIĆ
Plenary Speeches (1)
- Nathalie COLIN-OESTERLÉ
Plenary Speeches (1)
- Sylvia LIMMER
Institutional Motions (1)
- Markus BUCHHEIT
Institutional Motions (1)
- Virginie JORON
Plenary Speeches (1)
- Cristian TERHEŞ
Plenary Speeches (1)
- Cristina MAESTRE MARTÍN DE ALMAGRO
Plenary Speeches (1)
- Tomislav SOKOL
Plenary Speeches (1)
- Mikuláš PEKSA
Plenary Speeches (1)
- Petar VITANOV
Plenary Speeches (1)
- Cyrus ENGERER
Plenary Speeches (1)
- Vlad GHEORGHE
Plenary Speeches (1)
Votes
Transparence de l’Union au regard de la mise au point, de l’acquisition et de la distribution des vaccins contre la COVID-19 - Motions for resolutions - EU transparency in the development, purchase and distribution of COVID-19 vaccines - Entschließungsanträge - Transparenz in der EU in Bezug auf die Entwicklung, den Kauf und die Verteilung von COVID-19-Impfstoffen - B9-0519/2021 - Après le § 1 - Am 2 #
NI
The Left
Verts/ALE
Renew
S&D
PPEB9-0519/2021 - § 2 - Am 18 #
B9-0519/2021 - § 2 #
B9-0519/2021 - § 5 - Am 3 #
B9-0519/2021 - § 5 - Am 7 #
B9-0519/2021 - § 6 - Am 19 #
B9-0519/2021 - Après le § 6 - Am 20 #
B9-0519/2021 - § 7 - Am 8 #
B9-0519/2021 - § 8/1 #
B9-0519/2021 - § 8/2 #
B9-0519/2021 - Après le § 10 - Am 5 #
B9-0519/2021 - Après le § 10 - Am 21 #
B9-0519/2021 - Après le § 16 - Am 4 #
B9-0519/2021 - § 17 - Am 9 #
B9-0519/2021 - § 18 - Am 6 #
B9-0519/2021 - § 22/1 #
B9-0519/2021 - § 22/2 #
B9-0519/2021 - Après le visa 14 - Am 10 #
B9-0519/2021 - Après le visa 14 - Am 11 #
B9-0519/2021 - Après le visa 14 - Am 12 #
B9-0519/2021 - Visa 16 - Am 13 #
B9-0519/2021 - Après le visa 16 - Am 14 #
B9-0519/2021 - Après le considérant A - Am 15 #
B9-0519/2021 - Après le considérant B - Am 1 #
B9-0519/2021 - Après le considérant G - Am 16 #
B9-0519/2021 - Considérant K #
B9-0519/2021 - Après le considérant K - Am 17 #
B9-0519/2021 - Considérant M/1 #
B9-0519/2021 - Considérant M/2 #
Transparence de l’Union au regard de la mise au point, de l’acquisition et de la distribution des vaccins contre la COVID-19 - Motions for resolutions - EU transparency in the development, purchase and distribution of COVID-19 vaccines - Entschließungsanträge - Transparenz in der EU in Bezug auf die Entwicklung, den Kauf und die Verteilung von COVID-19-Impfstoffen - B9-0519/2021 - Proposition de résolution (ensemble du texte) #
History
(these mark the time of scraping, not the official date of the change)
| docs/4 |
|
| events/1 |
|
| procedure/Legislative priorities |
|
| docs/4 |
|
| events/1/summary |
|
| docs/4 |
|
| events/1 |
|
| forecasts |
|
| procedure/stage_reached |
Old
Awaiting plenary debate/voteNew
Procedure completed |
| procedure/title |
Old
EU-Transparency in the COVID-19 vaccine development, purchase and distributionNew
Resolution on EU transparency in the development, purchase and distribution of COVID-19 vaccines |
| docs/2 |
|
| docs/3 |
|
| forecasts/0/date |
Old
2021-10-19T00:00:00New
2021-10-21T00:00:00 |
| events |
|
| forecasts/0 |
|
| forecasts/0 |
|
| docs/1 |
|
| forecasts/0 |
|
| forecasts/0 |
|